Drug Trial Radar · NCT06264453
A Study to Evaluate the Efficacy and Safety of KH001 in Patients with Dentin Hypersensitivity
Last checked: Nov 19, 2026Latest source record: Mar 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
171
Actual
Start
Mar 19, 2024
Primary completion
Sep 25, 2024
Study completion Sep 25, 2024
Sponsor
- Lead sponsor
- HysensBio Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of KH001 in patients with dentin hypersensitivity.
Conditions
- Dentin Hypersensitivity
Interventions
KH001Drug
topical applications of KH001
PlaceboDrug
topical applications of Water for Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Schiff sensitivity scoreTime frame: Baseline and Day 36
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kyung Hee University Dental Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.